BIOMAT Database Logo BIOMAT Database Logo

Structure-activity relationships of quassinoids for eukaryotic protein synthesis. 2005

Narihiko Fukamiya, and Kuo-Hsiung Lee, and Ilias Muhammad, and Chihiro Murakami, and Masayohis Okano, and Isabelle Harvey, and Jerry Pelletier
Faculty of Integrated Arts and Sciences, Hiroshima University, Kagamiyama 1-7-1, Higashi, Hiroshima 739-8521, Japan.

The effect of 63 quassinoids on eukaryotic protein synthesis has been investigated. Seventeen of the tested compounds showed potent in vitro activity, with IC50s below 2 microM for inhibition in Krebs ascites translation extracts. Sixteen of these quassinoids were also potent inhibitors of in vivo protein synthesis when exposed to Hela cells for 1 h. Our results led to the following structure-activity relationships for quassinoids regarding translation inhibition. Activity is influenced by (i) the nature of the C-15 side chain, (ii) the nature of A ring modifications, (iii) the presence or absence of a sugar moiety, and (iv) the presence of an epoxymethano bridge.

UI MeSH Term Description Entries
D011500 Protein Synthesis Inhibitors Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. Protein Synthesis Antagonist,Protein Synthesis Antagonists,Protein Synthesis Inhibitor,Antagonist, Protein Synthesis,Antagonists, Protein Synthesis,Inhibitor, Protein Synthesis,Inhibitors, Protein Synthesis,Synthesis Antagonist, Protein,Synthesis Inhibitor, Protein
D005057 Eukaryotic Cells Cells of the higher organisms, containing a true nucleus bounded by a nuclear membrane. Cell, Eukaryotic,Cells, Eukaryotic,Eukaryotic Cell
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014176 Protein Biosynthesis The biosynthesis of PEPTIDES and PROTEINS on RIBOSOMES, directed by MESSENGER RNA, via TRANSFER RNA that is charged with standard proteinogenic AMINO ACIDS. Genetic Translation,Peptide Biosynthesis, Ribosomal,Protein Translation,Translation, Genetic,Protein Biosynthesis, Ribosomal,Protein Synthesis, Ribosomal,Ribosomal Peptide Biosynthesis,mRNA Translation,Biosynthesis, Protein,Biosynthesis, Ribosomal Peptide,Biosynthesis, Ribosomal Protein,Genetic Translations,Ribosomal Protein Biosynthesis,Ribosomal Protein Synthesis,Synthesis, Ribosomal Protein,Translation, Protein,Translation, mRNA,mRNA Translations
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D036702 Quassins A group of degraded TRITERPENES which have lost ten carbons (8 from the side chain, C17, and one from C4) so have C20 skeletons which could be misinterpreted as DITERPENES. They especially occur in plants of the SIMAROUBACEAE family. Quassinoid,Quassinoids,Simaroubolides

Related Publications

Narihiko Fukamiya, and Kuo-Hsiung Lee, and Ilias Muhammad, and Chihiro Murakami, and Masayohis Okano, and Isabelle Harvey, and Jerry Pelletier
Anti-inflammatory agents III: Structure-activity relationships of brusatol and related quassinoids.
November 1983, Journal of pharmaceutical sciences,
Narihiko Fukamiya, and Kuo-Hsiung Lee, and Ilias Muhammad, and Chihiro Murakami, and Masayohis Okano, and Isabelle Harvey, and Jerry Pelletier
Antitumor agents XLVIII: Structure-activity relationships of quassinoids as in vitro protein synthesis inhibitors of P-388 lymphocytic leukemia tumor cell metabolism.
April 1982, Journal of pharmaceutical sciences,
Narihiko Fukamiya, and Kuo-Hsiung Lee, and Ilias Muhammad, and Chihiro Murakami, and Masayohis Okano, and Isabelle Harvey, and Jerry Pelletier
Comparison of the in vitro activities of quassinoids with activity against Plasmodium falciparum, anisomycin and some other inhibitors of eukaryotic protein synthesis.
July 1990, Biochemical pharmacology,
Narihiko Fukamiya, and Kuo-Hsiung Lee, and Ilias Muhammad, and Chihiro Murakami, and Masayohis Okano, and Isabelle Harvey, and Jerry Pelletier
Structure-activity relationships for interferon induction and inhibition of protein synthesis by polynucleotides.
January 1981, Texas reports on biology and medicine,
Narihiko Fukamiya, and Kuo-Hsiung Lee, and Ilias Muhammad, and Chihiro Murakami, and Masayohis Okano, and Isabelle Harvey, and Jerry Pelletier
Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).
September 2009, The AAPS journal,
Narihiko Fukamiya, and Kuo-Hsiung Lee, and Ilias Muhammad, and Chihiro Murakami, and Masayohis Okano, and Isabelle Harvey, and Jerry Pelletier
Synthesis and structure-activity relationships of selective ligands for P3 purinoceptor-like protein (P3LP).
January 2000, Nucleic acids symposium series,
Narihiko Fukamiya, and Kuo-Hsiung Lee, and Ilias Muhammad, and Chihiro Murakami, and Masayohis Okano, and Isabelle Harvey, and Jerry Pelletier
Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D.
February 2011, ACS medicinal chemistry letters,
Narihiko Fukamiya, and Kuo-Hsiung Lee, and Ilias Muhammad, and Chihiro Murakami, and Masayohis Okano, and Isabelle Harvey, and Jerry Pelletier
Synthesis and structure-activity relationships of teixobactin.
January 2020, Annals of the New York Academy of Sciences,
Narihiko Fukamiya, and Kuo-Hsiung Lee, and Ilias Muhammad, and Chihiro Murakami, and Masayohis Okano, and Isabelle Harvey, and Jerry Pelletier
Assays for eukaryotic protein synthesis.
January 1979, Methods in enzymology,
Narihiko Fukamiya, and Kuo-Hsiung Lee, and Ilias Muhammad, and Chihiro Murakami, and Masayohis Okano, and Isabelle Harvey, and Jerry Pelletier
Myriaporone 3/4 structure--activity relationship studies define a pharmacophore targeting eukaryotic protein synthesis.
August 2006, Molecular bioSystems,
Copied contents to your clipboard!